Persons Reported to be living with HIV infection and with AIDS reported

Year Adults/Adolescents Children Under 13 Years old Total Cumulative Totals
  HIV AIDS HIV AIDS HIV AIDS Adults / Adolescents Children Under 13 Years old Total
2000 Confidential 43,606 Confidential 155 Confidential 43,761 43,606 155 43,761
2001 Confidential

45,285

Confidential 143 Confidential 45,428 45,285 143 45,428
2002 Confidential 52,562 Confidential 154 Confidential 52,716 52,562 154 52,716
                   

 

HIV Infection Cases  from areas with confidential HIV infection reporting

Year   Cumulative Totals
    Adults / Adolescents Children Under 13 Years old Total
2000 Confidential Confidential Confidential Confidential
2001 Confidential Confidential Confidential Confidential
2002 Confidential Confidential Confidential Confidential
         

 

Adult/Adolescent HIV infection and AIDS cases reported in the United States

Year Males Females
  HIV AIDS HIV AIDS
2000 Confidential 4,084 Confidential 629
2001 Confidential 3,741 Confidential 562
         

 

Pediatric AIDS cases reported

Year
2000 24
2001 12
2002 154
   

 

AIDS cases and annual rates per 100,000 population by Metropolitan area reported through 2001

 

 1999

2000

2001

Cumulative Totals

City No No. No. Adults / Adolescents Children under 13 Years old Total

Bakersfield

90 82 106 1,124 8 1,132
Fresno 65 93 56 1,252 14 1,266
Los Angeles 2,050 1,644 1,391 43,252 236 43,488
Oakland 345 272 320 8,304 43 8,347
Orange County 261 286 299 5,889 36 5,925
Riverside - San Bernardino 378 399 392 7,260 59 7,319
Sacramento 139 171 130 3,331 24 3,355
San Diego 547 439 478 11,015 55 11,070
San Francisco 851 762 596 28,391 47 28,438
San Jose 152 110 120 3,241 14 3,255
Stockton 61 37 26 781 13 794
Vallejo 110 64 90 1,465 11 1,476
Ventura 47 42 33 846 3 849

 

Cumulative AIDS Cases

Cumulative Number of AIDS Cases, Reported through 2002 128,064
Cumulative Number of Adult/Adolescent AIDS Cases, Reported through 2002 127,434
Cumulative Number of AIDS Cases in Children <13, Reported through 2002 630

Distribution of Cumulative Adult/Adolescent AIDS Cases by Gender, Reported through June 2002

  CA USA
Men 115,683 680,909
Women 9,516 146,298
Total 125,199 827,208

 

New AIDS Cases

New AIDS Cases, Reported through 2002 4,364
New Adult/Adolescent AIDS Cases, Reported in 2001 4,303
New AIDS Cases in Children <13, Reported through December 2001 12

Distribution of New Adult/Adolescent AIDS Cases by Gender, Reported in 2001

  CA USA
Men 3,741 31,901
Women 562 11,082
Total 4,303 42,983

 

Persons Living with AIDS

Estimated Number of Persons Living with AIDS at the End of 2002 52,176
Estimated Number of Adults/Adolescents Living with AIDS at the End of 2002 52,562
Estimated Number of Children Living with AIDS at the End of 2002 154
HIV Infection Cases Reported in 2002 Confidential

 

Total Deaths Reported through 2000, due to AIDS = 73,310
HIV Reporting Requirements ?   Yes, Code Based.
 
HIV Testing Options?  Anonymous and Confidential testing
Definitions:
Anonymous test: Individual does NOT use their name, and a name is not associated with test result. Anonymous tests are offered at anonymous testing centers, available in many, but not all, states.
Confidential test: Individual DOES use their name. If test is positive, individual's name will be known to their health care provider and, potentially, to other health care professionals and, in some cases, your state's Department of Health.
 
HIV Testing for Mothers and Newborns
Voluntary or Mandatory Testing?
 
Providers required to offer HIV test. Providers are required by law to offer HIV testing to pregnant women.
Voluntary HIV Testing: All states and the District of Columbia have certified to the CDC that they have measures in place to implement the CDC's 1995 recommendations on HIV counseling and testing of pregnant women.  The CDC's 1995 recommendations state that HIV testing of pregnant women and infants should be voluntary and providers must obtain informed consent for testing as required by their state laws.  Voluntary testing is noted if the state follows the CDC guidelines but does not have specific guidelines for testing of mothers and newborns.
 
Status of State Medicaid Expansion Efforts for People with HIV
Approved 1115 Waiver, TWWIIA demonstration?
NO,
Has considered or is considering an 1115 Waiver to expand Medicaid eligibility to people with HIV.
Definitions:
1115 Waivers: Section 1115 of the Social Security Act authorizes the executive branch of the Federal government to waive the statutory and regulatory provisions of the Medicaid program. States have used "1115 waivers" to make changes in eligibility, benefits, and other areas of their Medicaid programs. The Centers for Medicare and Medicaid Services (CMS--formerly known as the Health Care Financing Administration) and several states have been analyzing the implications of expanding Medicaid eligibility to people with HIV prior to disability through the use of Section 1115 waivers of the Social Security Act. To use 1115 waivers, states face several challenges, particularly the need to demonstrate "budget neutrality" to the Medicaid program - that the costs of an expansion over a designated period of time (usually 5 years) would not exceed the costs to Medicaid in the absence of the expansion.
Ticket to Work/Work Incentives Improvement Act of 1999: TWWIIA expanded State options under Medicaid by creating new Medicaid buy-in options for working individuals with disabilities and extended Medicare cover-age for working individuals with disabilities. The Act also authorized state demonstration programs to provide Medicaid to workers with potentially severe disabilities, including HIV/AIDS, who are not yet disabled but whose health conditions could be expected to cause disability.
Notes: Most people with HIV who qualify for Medicaid do so by meeting the program’s income and disability standards once their illness has already progressed. Many low income people with HIV may be faced with of having their eligibility postponed until they become disabled, even though there are therapies available that may prevent disability and national treatment guidelines recommend access to early treatment. 1115 Waivers and TWWIIA demonstrations are two ways in which states have sought to address this limitation.

 

Sterile Syringe Exchange Programs?  Yes,    State Law allows local governments to authorize syringe exchange if they declare a local emergency due to public health crisis.   

Notes:
U.S. totals include data from the United States (50 states and the District of Columbia), and from U.S. dependencies, possessions, and independent nations in free association with the United States.
Definitions: Programs in operation: includes both state-sanctioned syringe exchange programs and non-sanctioned programs. Because their operation may not necessarily be authorized, it is difficult to account for an exact number of syringe exchange programs operation across the country; therefore, the list may not be comprehensive.
 
STD/HIV/AIDS Education Requirement?  Yes, Must stress abstinence and cover contraception
 
Minors' Right to Consent to HIV/STD Services?  Yes, Minor must be at least 12 years of age. State explicitly classifies HIV/AIDS as an STD or infectious disease, for which minors may consent to testing. Law does not apply to HIV treatment.
 

 

Total Ryan White Funding, FY2000   $236,844,348 FY2002  $256,736,116

 

CDC HIV Prevention Funding for States
 FY2001
$15,662,315

FY2003   $15,853,584

 

Total Federal and State Funding for ADAP, FY2001  $147,896,630

Definitions: ADAPs: AIDS Drug Assistance Programs (ADAPs), authorized under Title II of the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, provide HIV-related prescription drugs to underinsured and uninsured individuals living with HIV/AIDS. Each state or territory administers its own ADAP.

 

AIDS Drug Assistance Programs (ADAPs)
Source Kaiser Family Foundation

 

Total ADAP Clients Served, June 2002  
  CA
#
US
#
   15,181 80,035

 
ADAP Clients Served by Sex, June 2002  
  CA
#
CA
%
US
#
US
%
  Male 13,756 91 62,034 78
  Female 1,394 9 16,702 21
  Total 15,181 100 79,531 100

 
ADAP Clients Served by Race/Ethnicity, June 2002  
  CA
#
CA
%
US
#
US
%
  White 6,793 45 29,426 37
  Black 1,895 12 26,245 33
  Hispanic 5,552 37 19,883 25
  Asian/Pacific Islander 229 2 795 1
  American Indian/Alaskan Native 56 0 795 1
  Other 656 4 795 1
  Total 15,181 100 79,531 100

 
ADAP Clients Served by Age, June 2002  
  CA
#
CA
%
US
#
US
%
  <13 years old 0 0 795 1
  13-19 years old 5 0 0 1 0 1
  20-44 years old 9,238 61 50,105 63
  >44 years old 5,902 39 27,836 35
  Total 15,181 100 79,531 100

 
ADAP Clients Served by Income, June 2002  
  CA
#
CA
%
US
#
US
%
  <100% FPL 6,390 42 38,175 48
  101-200% FPL 5,121 34 26,245 33
  201-300% FPL 2,368 16 8,748 11
  301-400% FPL 1,146 8 3,181 4
  >400% FPL 146 1 1,591 2
  Total 15,181 100 79,531 100

 
Insurance Coverage of ADAP Clients, June 2002  
  CA
#
CA
%
US
#
US
%
  Medicaid 1,753 12 0 10
  Medicare NA 2 NA 2 0 6
  Private 3,281 22 0 13

 
ADAP Financial Eligibility Criteria (% FPL), 2002  
  CA
%
US
%
   400 NA

 
National ADAP Budget, Total Federal and State Sources, FY 2002  
  CA
$
US
$
   161,412,081 878,610,754

 
National ADAP Budget by Source, FY 2002  
  CA
$
CA
%
US
$
US
%
  ADAP Earmark 82,051,914 51 619,830,000 71
  Title II Base 11,917,187 7 28,886,192 3
  State 67,442,980 42 160,385,979 18
  Title I 0 0 19,736,619 2
  Other Federal 0 0 30,941,439 4
  ADAP Supplemental Grants 0 0 19,170,000 2
  Total 161,412,081 100 878,610,754 100

 
Total ADAP Drug Expenditures, June 2002  
  CA
$
US
$
   14,891,578 70,705,142

 
ADAP Drug Expenditures by Drug Class, June 2002  
  CA
$
CA
%
US
$
US
%
  Nucleoside Reverse Transcriptase Inhibitors 7,277,843 49 31,486,146 49
  non-Nucleoside Reverse Transcriptase Inhibitors 1,607,680 11 7,940,575 12
  Protease Inhibitors 3,475,105 23 16,433,502 25
  Opportunistic Infections/Other 2,530,950 17 9,015,329 14
  Total 14,891,578 100 64,875,793 100

 
Total ADAP Prescriptions Filled, June 2002  
  CA
#
US
#
   60,675 257,279

 
ADAP Prescriptions Filled by Drug Class, June 2002  
  CA
#
CA
%
US
#
US
%
  Nucleoside Reverse Transcriptase Inhibitors 21,209 35 83,166 36
  non-Nucleoside Reverse Transcriptase Inhibitors 5,759 9 23,933 10
  Protease Inhibitors 8,398 14 33,813 15
  Opportunistic Infections/Other 25,309 42 87,746 38
  Total 60,675 100 228,771 100